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BSTRACT
 
Background
 
Standard clinical practice permits the
use of either single-chamber ventricular pacemakers
or dual-chamber pacemakers for most patients who
require cardiac pacing. Ventricular pacemakers are
less expensive, but dual-chamber pacemakers are
believed to be more physiologic. However, it is not
known whether either type of pacemaker results in
superior clinical outcomes.
 
Methods
 
The Pacemaker Selection in the Elderly
study was a 30-month, single-blind, randomized, con-
trolled comparison of ventricular pacing and dual-
chamber pacing in 407 patients 65 years of age or
older in 29 centers. Patients received a dual-chamber
pacemaker that had been randomly programmed to
either ventricular pacing or dual-chamber pacing.
The primary end point was health-related quality of
life as measured by the 36-item Medical Outcomes
Study Short-Form General Health Survey.
 
Results
 
The average age of the patients was 76
years (range, 65 to 96), and 60 percent were men.
Quality of life improved significantly after pacemak-
er implantation (P
 

 
0.001), but there were no differ-
ences between the two pacing modes in either the
quality of life or prespecified clinical outcomes (in-
cluding cardiovascular events or death). However, 53
patients assigned to ventricular pacing (26 percent)
were crossed over to dual-chamber pacing because
of symptoms related to the pacemaker syndrome.
Patients with sinus-node dysfunction, but not those
with atrioventricular block, had moderately better
quality of life and cardiovascular functional status
with dual-chamber pacing than with ventricular pac-
ing. Trends of borderline statistical significance in
clinical end points favoring dual-chamber pacing
were observed in patients with sinus-node dysfunc-
tion, but not in those with atrioventricular block.
 
Conclusions
 
The implantation of a permanent
pacemaker improves health-related quality of life.
The quality-of-life benefits associated with dual-
chamber pacing as compared with ventricular pac-
ing are observed principally in the subgroup of pa-
tients with sinus-node dysfunction. (N Engl J Med
1998;338:1097-104.)
 
©1998, Massachusetts Medical Society.
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ACEMAKER technology and clinical prac-
tice in the United States permit the use of
either single-chamber ventricular pacemak-
ers or dual-chamber pacemakers for patients
who require cardiac pacing. To date, the choice of
cardiac pacemaker has not been based on the results
of clinical trials. Ventricular pacemakers are less ex-
pensive, are simpler to implant and monitor, and
have a longer service life than dual-chamber pace-
makers. However, dual-chamber systems preserve
atrioventricular synchrony and may be more physio-
logic.
 
1
 
 Some studies have suggested that as com-
pared with patients with ventricular pacemakers, those
with dual-chamber pacemakers have a better health-
related quality of life.
 
2,3
 
 However, those small, cross-
over studies have had inconsistent blinding, have
occasionally used nonstandard means to measure
quality of life, and have been unable to assess wheth-
er improvements in the quality of life are maintained
during long-term follow-up. The purpose of the
Pacemaker Selection in the Elderly trial was to assess
the effect of the pacing mode on the long-term
health-related quality of life of elderly patients with
pacemakers.
 
METHODS
 
The study was a single-blind, randomized, controlled compar-
ison of ventricular pacing and dual-chamber pacing involving 29
centers. On the basis of statistical-power calculations, 400 pa-
tients were required in order to have a power of more than 80
percent to detect a clinically meaningful difference in the quality
P
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of life between treatment groups. Blocked randomization lists
were produced centrally for each site. Patient recruitment began
February 26, 1993, and ended September 30, 1994, when 407
patients had been enrolled. The patients were followed and clin-
ical end points were assessed until the initiation of the close-out
procedure, which began June 1, 1995, and ended August 31,
1995. After the close-out procedure was completed, the patients’
quality of life was assessed by telephone interviews through June
30, 1996. The average follow-up for clinical end points was 550
days (range, 216 to 996). 
All patients were 65 years of age or older, were in sinus rhythm,
required a permanent pacemaker for the prevention or treatment
of bradycardia,
 
4
 
 and gave written informed consent for research
participation. Intermedics dual-chamber rate-adaptive pacemakers
(models 294-03, 293-03, 294-03R, and 294-05) were implanted.
Patients were excluded from the study if they could not partici-
pate in the quality-of-life assessments, had clinically overt conges-
tive heart failure at the time of implantation, had had atrial fibril-
lation without any documented sinus mechanism for more than
six months, had serious noncardiac illness, or had inadequate atri-
al-capture or sensing thresholds.
 
Implantation and Programming
 
Once both atrial and ventricular leads had been positioned, a
randomization envelope was opened. The pacemaker was pro-
grammed to ventricular or dual-chamber pacing before implan-
tation. Randomization was stratified according to clinical site.
Initial programming in both groups required the use of rate ad-
aptation, which allows a sensor-based increase in the heart rate
proportional to a patient’s activity. Therefore, the formal mode
designations for the study were DDDR (atrial and ventricular
pacing, atrial and ventricular sensing, dual response, rate-adap-
tive) for dual-chamber pacemakers and VVIR (ventricular pacing,
ventricular sensing, inhibition response, rate-adaptive) for ventric-
ular pacemakers.
 
5
 
 For both groups, a lower rate limit of at least
50 beats per minute was required, and an upper limit of less than
130 beats per minute was suggested. Programming of all other
features was left to the discretion of the investigators.
 
Patient Monitoring
 
Follow-up visits and health-status assessments took place 3, 9,
and 18 months after enrollment and at the end of the study. The
assessment of health status before randomization was performed
at the local clinical site, before the pacemaker mode was assigned.
Subsequent assessments were made by telephone from the coor-
dinating center by two experienced telephone interviewers who
were unaware of the patients’ mode assignments. The first inter-
viewer conducted 98 percent of the 3-month interviews, whereas
the second interviewer conducted 98 percent of the 9-month in-
terviews and 99 percent of the 18-month interviews.
Multidimensional health-related quality of life was assessed with
the 36-item Medical Outcomes Study Short-Form General Health
Survey (SF-36),
 
6
 
 which includes one multi-item scale measuring
eight health-related aspects: physical function, social function,
physical role, emotional role, mental health, energy, pain, and gen-
eral health perceptions. The score on each of the eight health con-
cepts ranges from 0 (worst) to 100 (best). For example, the average
physical-function score for a healthy 70-year-old person is 69,
whereas the average score for a patient of similar age but with con-
gestive heart failure is 48.
 
7
 
 Disease-specific cardiovascular function-
al status was measured with the Specific Activity Scale.
 
8
 
 The score
on this four-point scale ranges from 1 (best) to 4 (worst). We val-
idated the SF-36 by comparing subgroups of study patients with
diagnoses known to affect quality of life, such as heart failure or
angina, and those without such diagnoses.
 
End Points
 
The primary end point was health-related quality of life as
measured by the SF-36. In addition, we compared the following
prespecified secondary clinical end points between groups: death
from all causes; first nonfatal stroke or death; first hospitalization
for heart failure, first nonfatal stroke, or death; development of
atrial fibrillation; and development of the pacemaker syndrome.
All the components of the composite end points were chosen on
the basis of data in the pacing literature suggesting the potential
for improvement with atrial-based pacing.
 
9
 
 The pacemaker syn-
drome (which is related to a sustained loss of synchronous atrio-
ventricular contraction) was defined as the presence of left-sided
or right-sided heart failure in association with ventricular pacing
or of symptomatic hypotension with a drop in blood pressure of
20 mm Hg or more during ventricular pacing. We also analyzed
prespecified subgroups of patients with a diagnosis at implanta-
tion of sinus-node dysfunction or atrioventricular block.
 
Statistical Analysis
 
Base-line characteristics were compared between treatment
groups with use of Wilcoxon’s rank-sum test for continuous
measures and Fisher’s exact test for categorical variables. We used
Wilcoxon’s signed-rank tests for paired data to assess changes that
occurred after randomization in all patients and changes that oc-
curred after crossover to dual-chamber pacing in patients with
ventricular pacing. All analyses were based on the intention to
treat. Scores for the SF-36 subscales were compared between
modes at each period with a multiple linear regression analysis,
with adjustment for sex, quartile of age, and the base-line score
for the specific subscale. Scores for the Specific Activity Scale were
compared between treatment groups with an ordinal logistic re-
gression adjusted for sex, quartile of age, and base-line score for
the specific patient. In addition, longitudinal mode-related differ-
ences were analyzed with generalized estimating equations.
 
10
 
 For
scores for the SF-36 subscales, a repeated-measures linear regres-
sion was used. For the scores for the Specific Activity Scale, the
general-estimating-equation analogue of a binomial model was
used. The design of the study necessarily permitted reprogram-
ming from ventricular to dual-chamber pacing if severe pacemak-
er syndrome developed in patients assigned to ventricular pacing.
In each such patient, scores for the SF-36 and Specific Activity
Scale were assessed before crossover, and these scores were carried
forward for subsequent statistical analyses of quality of life. The
length of time to the occurrence of the clinical end points in each
group was compared visually with use of Kaplan–Meier curves
 
11
 
and inferentially with use of the Cox proportional-hazards
method
 
12
 
 adjusted for sex and quartile of age. For all analyses, the
P values were two-tailed, and a P value of less than 0.05 was con-
sidered to indicate statistical significance.
 
RESULTS
 
Base-Line Characteristics
 
The average age of the patients was 76 (range, 65
to 96), and 60 percent were men. Over 70 percent of
the overall population was in New York Heart Asso-
ciation class I or II. Twenty-nine percent of the pa-
tients had a history of supraventricular tachycardia,
including atrial fibrillation, and 27 percent had a his-
tory of heart failure. Cerebrovascular disease was
present at base line in 13 percent. The ejection frac-
tion was known in the case of 254 patients (62 per-
cent) and was normal in 56 percent of these. Antiar-
rhythmic therapy was in use in 17 percent of patients.
There were no significant differences in any of the
base-line characteristics between groups (Table 1).
 
Indications for and Characteristics of the Pacemakers
 
The indications for the implantation of a perma-
nent pacemaker included atrioventricular block in
The New England Journal of Medicine 
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201 patients (49 percent, of whom 119 patients, or
59 percent, had third-degree block), sinus-node
dysfunction in 175 patients (43 percent), and other
diagnoses in 31 (8 percent). Ventriculoatrial (retro-
grade) conduction at the time of implantation was
present in 29 percent. There were no important dif-
ferences in capture and sensing thresholds between
groups at the time of implantation (Table 2).
 
Pacemaker Syndrome
 
During the course of the trial, pacemaker syn-
drome severe enough to warrant reprogramming
from ventricular to dual-chamber pacing was diag-
nosed in 53 patients assigned to ventricular pacing
(26 percent), in 45 percent of whom sinus-node
dysfunction was the reason for implantation. Cross-
over from ventricular to dual-chamber pacing oc-
curred early: 44 percent of the 53 crossovers oc-
curred within one month after implantation, and 77
percent within six months (Fig. 1). Although multi-
ple symptoms were recorded in each patient, the
clinical manifestations were fatigue in all patients,
dyspnea or effort intolerance in 67 percent, orthop-
nea or paroxysmal nocturnal dyspnea in 24 percent,
presyncope in 33 percent, and a feeling of fullness in
the neck in 20 percent. After crossover, the patients
had improvement in SF-36 scores, including scores
for physical function (
 

 
22, P
 

 
0.03) and emotional
role (
 

 
27, P
 

 
0.01).
 
Other Changes in Assigned Mode
 
Four patients (2 percent) who were initially as-
signed to dual-chamber pacing had their pacemakers
reprogrammed to single-chamber ventricular pacing
during the course of the study because chronic atrial
fibrillation or supraventricular tachycardia developed
(P
 

 
0.001 for the comparison with the crossover
rate in the ventricular-pacing group).
 
Validation of SF-36
 
Patients with a history of heart failure at base line
were compared with those without such a history.
There was a 13-point difference in scores for the phys-
ical-function subscale of SF-36 (44 vs. 57, P
 

 
0.001)
and a 13-point difference in scores for the physical-
role subscale (25 vs. 38, P
 

 
0.004). Patients with a
base-line history of angina were compared with those
without angina. There was a 10-point difference in
scores for the physical-function subscale (47 vs. 57,
P
 

 
0.001) and a 14-point difference in scores for the
physical-role subscale (25 vs. 39, P
 

 
0.002).
 
Quality of Life
 
In the overall group, there was significant im-
provement in health-related quality of life between
base line (before implantation) and three months
after implantation, as measured by several SF-36
subscales (social function, P
 

 
0.001; physical role,
 
*Plus–minus values are means 
 

 
SD. NYHA denotes New York Heart
Association. There were no significant differences between groups. 
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Age (yr) 76
 

 
6 76
 

 
7
Male sex (%) 62 57
Nonwhite race (%) 14 12
NYHA class I or II (%) 73 70
History (%)
Diabetes
Hypertension
Myocardial infarction
Heart failure
Depressed ejection fraction
Supraventricular tachycardia
Cerebrovascular disease
Chronic lung disease
Any tumor
25
51
33
28
25
30
14
13
8
29
52
33
26
27
27
12
14
10
Prior procedures or operations (%)
Coronary bypass surgery
Mitral-valve surgery
Aortic-valve surgery
Coronary angioplasty
Implantation of defibrillator
Radiofrequency ablation
22
3
4
7
1
1
23
3
4
10
1
1
Concomitant medications (%)
Angiotensin-converting–
enzyme inhibitors
Amiodarone
Aspirin
 
b
 
-Adrenergic blockers
Calcium antagonists
Warfarin
Digitalis
Diuretics
Flecainide
Procainamide
Quinidine
Sotalol
27
5
37
16
24
4
23
36
2
5
1
3
31
4
41
9
26
6
17
34
2
7
2
4
*Plus–minus values are means 
 

 
SD.
†Capture threshold was measured at a pulse width of 0.5 msec.
‡Ventriculoatrial conduction was assessed by ventricular pacing at 70
and 100 beats per minute.
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P-wave amplitude (mV) 3.2
 

 
1.5 3.0
 

 
1.3 0.29
Atrial-capture threshold (V)† 1.0
 

 
0.4 1.0
 

 
0.4 0.33
R-wave amplitude (mV) 12.8
 

 
5.3 12.0
 

 
5.2 0.16
Ventricular-capture
threshold (V)†
0.5
 

 
0.2 0.6
 

 
0.3 0.02
Ventriculoatrial conduc-
tion at implantation 
(% of patients)‡
29 29 1.00
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P
 

 
0.001; emotional role, P0.001; mental health,
P0.001; energy, P0.001). In contrast, there were
no significant differences in scores between the ven-
tricular-pacing group and the dual-chamber–pacing
group in any of the SF-36 subscales at 3 months or
18 months. After nine months of follow-up, there
was a significant difference favoring dual-chamber
pacing only in scores for the mental health subscale
(P0.03) (Table 3). Longitudinal analyses, howev-
er, detected a borderline improvement in scores on
the emotional-role subscale in patients assigned to
dual-chamber pacing (P0.04). There were no sig-
nificant differences in cardiovascular functional sta-
tus between groups, as assessed by the Specific
Activity Scale, at either the three-month or the nine-
month assessment. However, there was a significant
difference favoring dual-chamber pacing at the 18-
month visit (Table 4), and longitudinal analysis dem-
onstrated a significant difference favoring dual-cham-
ber pacing (P0.045).
Clinical Events
There were no significant differences between the
ventricular-pacing group and the dual-chamber–
pacing group in the rates of death from all causes,
stroke or death, stroke or death or hospitalization
for heart failure, and the development of atrial fibril-
lation (Table 5).
Analysis of Prespecified Subgroups
Sinus-Node Dysfunction
Among the patients who received pacemakers be-
cause of sinus-node dysfunction, there were signifi-
cant differences favoring dual-chamber pacing at
three months in scores on the physical-role subscale
(P0.02), social-function subscale (P0.03), and
emotional-role subscale (P0.002) of SF-36. Al-
though in the later assessments there were no signif-
icant differences between treatment groups at each
time point, longitudinal analyses demonstrated bet-
ter scores on the emotional-role subscale (P0.001)
and social-function subscale (P0.02) in the pa-
tients assigned to dual-chamber pacing. Longitudi-
nal analysis of scores on the Specific Activity Scale
demonstrated a significant difference favoring dual-
chamber pacing (P0.02). Furthermore, there were
trends of borderline significance in clinical end points
favoring dual-chamber pacing (Table 5). 
Atrioventricular Block
Among the patients with atrioventricular block at
implantation, there were no significant differences
between groups in any of the SF-36 subscales, in lon-
gitudinal analyses of the Specific Activity Scale, or in
any of the prespecified clinical end points (Table 5).
DISCUSSION
Industry sources estimate that nearly 190,000
pacemakers will be implanted in patients in the
United States in 1998, a substantial increase since
1989, when 110,500 devices were implanted.13 Al-
though dual-chamber pacemakers have been in
common use for nearly two decades, the effect of
the type of pacemaker on the long-term health-
related quality of life of elderly pacemaker recipients
has not been adequately studied.
Over 70 percent of pacemaker recipients are at
least 70 years old,14 and there are sound physiologic
reasons to expect that maintenance of atrioventricu-
lar synchrony with a dual-chamber pacemaker might
Figure 1. Kaplan–Meier Curve of the Proportion of Patients Assigned to Ventricular
Pacing Who Did Not Cross Over to Dual-Chamber Pacing.
The tick marks represent the time to crossover or the end of follow-up.
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be desirable in elderly patients.15,16 However, dual-
chamber pacemakers are more expensive and more
difficult to implant and monitor than single-cham-
ber ventricular pacemakers, and dual-chamber pace-
makers carry a risk of complications in two leads,
not just one.17 In the present cohort, pacemaker
placement led to dramatic improvements in health-
related quality of life. This uncontrolled observation
is consistent with the reported low rate of recurrence
of symptoms after pacemaker implantation.18 How-
ever, when patients with ventricular pacing were
compared with patients with dual-chamber pacing,
there were no convincing differences in general
health-related quality of life. Analysis of two pre-
specified subgroups — patients with sinus-node dys-
function and those with atrioventricular block at
implantation — did reveal a favorable response to
dual-chamber pacing in patients with sinus-node
dysfunction. Nonetheless, these differences are con-
siderably smaller than were previously thought. In
contrast to the pattern observed with respect to gen-
eral quality of life in the overall group, the Specific
Activity Scale, an instrument that specifically meas-
ures the physical limitations associated with cardio-
*The numbers of patients are the numbers eligible for evaluation. VVIR denotes rate-adaptive single-chamber ventricular pacing, and DDDR rate-adap-
tive dual-chamber pacing. Means and P values were adjusted by multiple regression for sex and quartile of age and, at follow-up, for base-line functional
status. Patients who died were excluded from the analysis, and patients who enrolled too late for the 18-month interview were not included in the analysis
at 18 months.
TABLE 3. QUALITY OF LIFE BEFORE AND AFTER PACEMAKER IMPLANTATION, ACCORDING TO THE SCORES ON THE SF-36.*
VARIABLE BASE LINE 3 MONTHS 9 MONTHS 18 MONTHS
VVIR
(N204)
DDDR
(N203)
P
VALUE
VVIR
(N167)
DDDR
(N160)
P
VALUE
VVIR
(N165)
DDDR
(N163)
P
VALUE
VVIR
(N150)
DDDR
(N138)
P
VALUE
Percentage of eligible 
patients evaluated
100 100 85 81 88 87 92 88
score score score score
Subscale
Physical function
Social function
Physical role
Emotional role
Mental health
Energy
Pain
Health perception
52.9
61.3
33.4
70.6
73.0
43.9
67.3
60.3
54.4
63.4
35.9
67.2
71.9
42.3
66.1
60.3
0.55
0.45
0.54
0.41
0.59
0.52
0.67
0.97
53.9
73.0
53.6
83.8
77.0
53.0
69.7
62.3
56.9
75.3
62.8
90.6
77.6
55.0
69.4
62.2
0.23
0.37
0.051
0.052
0.73
0.35
0.91
0.99
54.0
67.3
49.0
76.5
75.2
50.3
72.1
58.4
57.5
69.2
53.2
81.1
79.0
50.5
70.9
58.3
0.22
0.54
0.36
0.27
0.03
0.92
0.64
0.95
58.4
68.0
53.7
76.1
73.0
50.1
68.2
58.3
58.4
69.9
55.1
80.6
76.5
50.1
70.6
56.2
0.99
0.54
0.78
0.31
0.09
0.99
0.42
0.33
*The numbers of patients are the numbers eligible for evaluation. VVIR denotes rate-adaptive single-chamber ventric-
ular pacing, and DDDR rate-adaptive dual-chamber pacing. Patients who died were excluded from the analysis, and pa-
tients enrolled too late for the 18-month interview were not included in the analysis at 18 months. P values and propor-
tions shown are from an unadjusted chi-square test for trend.
TABLE 4. CARDIOVASCULAR FUNCTIONAL STATUS BEFORE AND AFTER PACEMAKER IMPLANTATION, 
ACCORDING TO THE SCORES ON THE SPECIFIC ACTIVITY SCALE.*
VARIABLE BASE LINE 3 MONTHS 9 MONTHS 18 MONTHS
VVIR
(N204)
DDDR
(N203)
VVIR
(N159)
DDDR
(N158)
VVIR
(N155)
DDDR
(N161)
VVIR
(N141)
DDDR
(N136)
Percentage of 
eligible patients
evaluated 
100 100 81 80 83 86 87 87
percentage of patients
Score on Specific 
Activity Scale
1 (best)
2
3
4 (worst)
37
25
37
1
39
20
38
2
41
22
34
3
44
27
27
3
47
25
26
3
55
22
23
1
46
23
26
6
60
15
24
1
P value 0.71 0.22 0.23 0.02
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vascular disease, detected differences favoring dual-
chamber pacing that increased over time and were
significant in longitudinal analyses.
Prior studies have suggested a measurably superi-
or quality of life in patients with dual-chamber pac-
ing, and on the basis of these studies we expected
dual-chamber pacing to have a greater benefit than
we actually found. There are important method-
ologic differences that may account for our diver-
gent results. Some studies have used a short-term
crossover design19 or measured quality of life with
nonstandard instruments that have not been validat-
ed.2 We measured quality of life with a standard
instrument and validated it against known disease
states within the study population. Follow-up in
crossover studies is short, and the long-term effects
of any given pacemaker mode cannot be assessed.
Blinding in crossover studies may be difficult, and
investigator bias may occur. Our use of a long-term,
parallel study design with quality-of-life interviewers
who were unaware of patients’ treatment assign-
ments obviated many of these problems and may ac-
count for our unexpected results.
The apparently divergent results of a generic in-
strument (SF-36) and a cardiovascular disease–spe-
cific instrument (the Specific Activity Scale) assess-
ing quality of life in the overall group emphasize the
complexities inherent in measuring this variable in
the elderly. Although it is clear from our results that
dual-chamber pacing is associated with long-term
improvements in cardiovascular function, the impor-
tance of aging and of the development of other con-
ditions may overwhelm the moderate improvements
in cardiovascular functional class and minimize the
long-term effect on general quality of life.
The pacemaker syndrome20,21 most often mimics
left-sided or right-sided congestive heart failure with
or without associated left ventricular systolic dys-
function, or it may present with autonomic dysfunc-
tion,22 hypotension, and associated symptoms. The
syndrome is related to the loss of synchronous atri-
oventricular conduction. The reported incidence of
the pacemaker syndrome varies widely, from 1.7 per-
cent23 to 83 percent.2 Our results mandate a cautious
interpretation of the crossover statistics. Crossovers
occurred when symptoms of possible pacemaker syn-
drome reached a clinical threshold for reprogram-
ming to dual-chamber pacing. Consequently, it is
not surprising that we report an intermediate inci-
dence of reprogramming to a dual-chamber mode.
Nevertheless, over 70 percent of patients who were
assigned to ventricular pacing and were alive at the
end of the study were still in their assigned mode.
Thus, on the basis of quality-of-life considerations
alone, many patients who receive dual-chamber pace-
makers might fare just as well with ventricular sys-
tems. However, more investigative effort should be
focused on finding simple ways in which to identify
preoperatively the minority of patients who will prove
intolerant to ventricular pacing.
The literature on cardiac pacing is replete with
retrospective analyses associating dual-chamber or
atrial pacing with improved clinical outcomes.9,24-26
However, all these retrospective studies are flawed
because pacemaker selection was not random and
because clinicians selected the more expensive forms
of technology for younger, less sick patients. In a
late follow-up of a prospective study of patients with
sinus-node dysfunction, Andersen et al.23 reported
that atrial pacing reduced embolic events, atrial fi-
brillation, and mortality. We found that there was
no significant mode-related difference in either the
incidence of atrial fibrillation or any of the other
prespecified clinical end points in the overall group.
However, analyses of subgroups of patients with si-
nus-node dysfunction revealed trends similar to the
findings reported by Andersen et al.23 Patients with
atrioventricular block did not demonstrate any clear
benefit from dual-chamber pacing. This finding in
patients with atrioventricular block is consistent with
*VVIR denotes rate-adaptive single-chamber ventricular pacing, and DDDR rate-adaptive dual-chamber pacing.
TABLE 5. ANALYSIS OF THE END POINTS IN THE GROUP AS A WHOLE AND AMONG PATIENTS WITH SINUS-NODE DYSFUNCTION 
OR ATRIOVENTRICULAR BLOCK AT IMPLANTATION.*
PRESPECIFIED END POINT OVERALL POPULATION SINUS-NODE DYSFUNCTION ATRIOVENTRICULAR BLOCK
VVIR
(N204)
DDDR
(N203) P VALUE
VVIR
(N85)
DDDR
(N90) P VALUE
VVIR
(N102)
DDDR
(N99) P VALUE
no. (%) no. (%) no. (%)
Death from all causes 34 (17) 32 (16) 0.95 17 (20) 11 (12) 0.09 15 (15) 17 (17) 0.41
Stroke or death from any cause 39 (19) 35 (17) 0.75 19 (22) 12 (13) 0.11 18 (18) 18 (18) 0.68
Stroke or hospitalization for heart failure
or death from any cause 
56 (27) 44 (22) 0.18 26 (31) 18 (20) 0.07 27 (26) 21 (21) 0.49
Atrial fibrillation 38 (19) 35 (17) 0.80 24 (28) 17 (19) 0.06 11 (11) 16 (16) 0.26
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the reported failure to find a clear difference in exer-
cise duration in patients with atrioventricular block
with rate-adaptive pacing, ventricular pacing, or dual-
chamber pacing.27-30 
The design of the study did not permit mainte-
nance of an accurate registry to compare the screened
and enrolled populations. However, the demographic
and clinical characteristics of the participants were
very similar to those of recipients of dual-chamber
pacemakers in the Medicare data base.26 Frequent
ventricular pacing might be associated with the devel-
opment of the pacemaker syndrome.31 However, the
pacemakers used in this trial did not have accurate in-
ternal event counters, and the frequency of paced
ventricular events is unknown. The use of rate adap-
tation may obscure differences between dual-chamber
and ventricular pacing. The importance of this possi-
bility cannot be assessed, since our study did not
include a comparison group with simple ventricular-
demand pacing. The difference in clinical events
between groups may have been reduced by the cross-
over rate. The study was designed with good statisti-
cal power to detect clinically relevant differences in
health-related quality of life. However, the statistical
design still permitted a 20 percent likelihood of a false
negative result. Finally, there was only limited statisti-
cal power to address differences in clinical events.
In the study, health-related quality of life improved
dramatically after pacemaker implantation; however,
general quality-of-life benefits associated with dual-
chamber pacing as opposed to ventricular pacing
were detectable only in the subgroup of patients with
sinus-node dysfunction. These benefits were moder-
ate. The interpretation of the quality-of-life results
must be tempered by the rather high crossover rates
from ventricular pacing to dual-chamber pacing and
by strong trends toward clinical benefit in patients as-
signed to dual-chamber pacing, particularly in those
with sinus-node dysfunction.
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APPENDIX
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Marshfield, Wis.; N. Tullo, St. Joseph’s Hospital and Medical Center,
Patterson, N.J.; S. Greenberg, St. Francis Hospital, Roslyn, N.Y.; H. Wein-
er, Delaware Cardiology Research Foundation, Newark, Del.; C. Love,
Ohio State University, Cleveland; C. Dennis, Deborah Heart and Lung
Center, Browns Mills, N.J.; R. Henthorn, Christ Hospital, Cincinnati; J.
Herre, Cardiology Consultants, Norfolk, Va.; O. Randall, Howard Univer-
sity Hospital, Washington, D.C.; D. Bush, Francis Scott Key Medical Cen-
ter, Baltimore; C. Clyne, University of Pennsylvania Medical Center, Phil-
adelphia; L. Beauregard, Cooper Hospital, Camden, N.J.; T. Friehling,
Fairfax Hospital, Fairfax, Va.; C. Schuger, Beth Israel Deaconess Medical
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REFERENCES
1. Samet P, Castillo C, Bernstein WH. Hemodynamic consequences of 
atrial and ventricular pacing in subjects with normal hearts. Am J Cardiol 
1966;18:522-5.
2. Heldman D, Mulvihill D, Nguyen H, et al. True incidence of pacemaker 
syndrome. Pacing Clin Electrophysiol 1990;13:1742-50.
3. Sulke N, Dritsas A, Bostock J, Wells A, Morris R, Sowton E. “Subclin-
ical” pacemaker syndrome: a randomised study of symptom free patients 
with ventricular demand (VVI) pacemakers upgraded to dual chamber de-
vices. Br Heart J 1992;67:57-64.
4. Dreifus LS, Fisch C, Griffin JC, Gillette PC, Mason JW, Parsonnet V. 
Guidelines for implantation of cardiac pacemakers and antiarrhythmia de-
vices: a report of the American College of Cardiology/American Heart As-
sociation Task Force on Assessment of Diagnostic and Therapeutic Cardio-
vascular Procedures (Committee on Pacemaker Implantation). Circulation 
1991;84:455-67.
5. Bernstein AD, Camm AJ, Fletcher RD, et al. The NASPE/BPEG ge-
neric pacemaker code for antibradyarrhythmia and adaptive-rate pacing and 
antitachyarrhythmia devices. Pacing Clin Electrophysiol 1987;10:794-9.
6. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health 
Survey (SF-36). I. Conceptual framework and item selection. Med Care 
1992;30:473-83.
7. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey: manual 
and interpretation guide. Boston: Health Institute, New England Medical 
Center, 1993.
8. Goldman L, Hashimoto B, Cook EF, Loscalzo A. Comparative reproduc-
ibility and validity of systems for assessing cardiovascular functional class: ad-
vantages of a new Specific Activity Scale. Circulation 1981;64:1227-34.
9. Rosenqvist M, Brandt J, Schuller H. Long-term pacing in sinus node 
disease: effects of stimulation mode on cardiovascular morbidity and mor-
tality. Am Heart J 1988;116:16-22.
10. Diggle PJ, Liang K-Y, Zeger SL. Analysis of longitudinal data. Oxford, 
England: Oxford University Press, 1994.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete ob-
servations. J Am Stat Assoc 1958;53:457-81.
12. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34:
187-220.
13. Bernstein AD, Parsonnet V. Survey of cardiac pacing in the United 
States in 1989. Am J Cardiol 1992;69:331-8.
14. Lamas GA, Prosser AP, Edery TP, Lee MT, Berman KE, Levine PA. 
Age and sex bias in pacemaker selection. Circulation 1992;86:Suppl I:
I-449. abstract.
15. Bonow RO, Vitale DF, Bacharach SL, Maron BJ, Green MV. Effects 
of aging on asynchronous left ventricular regional function and global ven-
tricular filling in normal human subjects. J Am Coll Cardiol 1988;11:50-8.
16. Miller TR, Grossman SJ, Schectman KB, Biello DR, Ludbrook PA, 
Ehsani AA. Left ventricular diastolic filling and its association with age. Am 
J Cardiol 1986;58:531-5.
17. Brinker JA. Endocardial pacing leads: the good, the bad, and the ugly. 
Pacing Clin Electrophysiol 1995;18:953-4.
18. Lamas GA, Dawley D, Splaine K, Folland ED, Friedman PL, Antman 
EM. Documented symptomatic bradycardia and symptom relief in patients 
receiving permanent pacemakers: an evaluation of the joint ACC/AHA 
pacing guidelines. Pacing Clin Electrophysiol 1988;11:1098-104.
19. Linde-Edelstam C, Nordlander R, Unden AL, Orth-Gomer K, Ryden 
L. Quality-of-life in patients treated with atrioventricular synchronous pac-
ing compared to rate modulated ventricular pacing: a long-term, double-
blind, crossover study. Pacing Clin Electrophysiol 1992;15:1467-76.
20. Furman S. Pacemaker syndrome. Pacing Clin Electrophysiol 1994;17:
1-5.
21. Ellenbogen KA, Gilligan DA, Wood MA, Morillo C, Barold SS. The 
pacemaker syndrome — a matter of definition. Am J Cardiol 1997;79:
1226-9.
22. Ellenbogen KA, Thames MD, Mohanty PK. New insights into pace-
maker syndrome gained from hemodynamic, humoral and vascular re-
sponses during ventriculo-atrial pacing. Am J Cardiol 1990;65:53-9.
23. Andersen HR, Nielsen JC, Thomsen PEB, et al. Long-term follow-up 
of patients from a randomised trial of atrial versus ventricular pacing for 
sick-sinus syndrome. Lancet 1997;350:1210-6.
24. Hesselson AB, Parsonnet V, Bernstein AD, Bonavita GJ. Deleterious 
effects of long-term single-chamber ventricular pacing in patients with sick 
sinus syndrome: the hidden benefits of dual chamber pacing. J Am Coll 
Cardiol 1992;19:1542-9.
25. Lamas GA, Estes NM III, Schneller S, Flaker GC. Does dual chamber 
The New England Journal of Medicine 
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 21, 2015. For personal use only. No other uses without permission. 
 Copyright © 1998 Massachusetts Medical Society. All rights reserved. 
1104  Apr i l  16, 1998
The New England Journal  of  Medicine
or atrial pacing prevent atrial fibrillation? The need for a randomized con-
trolled trial. Pacing Clin Electrophysiol 1993;15:1109-13.
26. Lamas GA, Pashos CL, Normand SLT, McNeil B. Permanent pace-
maker selection and subsequent survival in elderly Medicare pacemaker re-
cipients. Circulation 1995;91:1063-9.
27. Pehrsson SK. Influence of heart rate and atrioventricular synchroniza-
tion on maximal work tolerance in patients treated with artificial pacemak-
ers. Acta Med Scand 1983;214:311-5.
28. Jutzy RV, Florio J, Isaeff DM, et al. Comparative evaluation of rate 
modulated dual chamber and VVIR pacing. Pacing Clin Electrophysiol 
1990;13:1838-46.
29. Linde-Edelstam C, Hjemdahl P, Pehrsson SK, Astrom H, Nordlander 
R. Is DDD pacing superior to VVI,R? A study on cardiac sympathetic 
nerve activity and myocardial oxygen consumption at rest and during ex-
ercise. Pacing Clin Electrophysiol 1992;15:425-34.
30. Deharo JC, Badier M, Thirion X, et al. A randomized, single-blind 
crossover comparison of the effects of chronic DDD and dual sensor VVIR 
pacing mode on quality-of-life and cardiopulmonary performance in com-
plete heart block. Pacing Clin Electrophysiol 1996;19:1320-6.
31. Rediker DE, Eagle KA, Homma S, Gillam LD, Harthorne JW. Clinical 
and hemodynamic comparison of VVI versus DDD pacing in patients with 
DDD pacemakers. Am J Cardiol 1988;61:323-9.
The New England Journal of Medicine 
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 21, 2015. For personal use only. No other uses without permission. 
 Copyright © 1998 Massachusetts Medical Society. All rights reserved. 
